US 9,809,819 B2
Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
Bob D. Brown, Millington, NJ (US)
Assigned to DICERNA PHARMACEUTICALS, INC., Cambridge, MA (US)
Filed by Dicerna Pharmaceuticals, Inc., Watertown, MA (US)
Filed on Nov. 3, 2014, as Appl. No. 14/531,913.
Application 14/531,913 is a division of application No. 13/738,024, filed on Jan. 10, 2013, granted, now 9,200,284.
Application 13/738,024 is a division of application No. 12/754,427, filed on Apr. 5, 2010, granted, now 8,372,816, issued on Feb. 12, 2013.
Application 12/754,427 is a continuation in part of application No. PCT/US2009/005214, filed on Sep. 17, 2009.
Application PCT/US2009/005214 is a continuation in part of application No. 12/642,264, filed on Dec. 18, 2009, abandoned.
Application 12/642,264 is a continuation in part of application No. 12/642,404, filed on Dec. 18, 2009, abandoned.
Application 12/642,404 is a continuation in part of application No. 12/642,371, filed on Dec. 18, 2009, granted, now 8,513,207, issued on Aug. 20, 2013.
Application 12/642,371 is a continuation in part of application No. 12/704,256, filed on Feb. 11, 2010, abandoned.
Claims priority of provisional application 61/309,266, filed on Mar. 1, 2010.
Claims priority of provisional application 61/285,925, filed on Dec. 11, 2009.
Claims priority of provisional application 61/257,810, filed on Nov. 3, 2009.
Claims priority of provisional application 61/257,820, filed on Nov. 3, 2009.
Claims priority of provisional application 61/184,735, filed on Jun. 5, 2009.
Claims priority of provisional application 61/183,818, filed on Jun. 3, 2009.
Claims priority of provisional application 61/183,815, filed on Jun. 3, 2009.
Claims priority of provisional application 61/174,306, filed on Apr. 30, 2009.
Claims priority of provisional application 61/174,279, filed on Apr. 30, 2009.
Claims priority of provisional application 61/166,578, filed on Apr. 3, 2009.
Claims priority of provisional application 61/166,559, filed on Apr. 3, 2009.
Claims priority of provisional application 61/151,841, filed on Feb. 11, 2009.
Prior Publication US 2015/0057337 A1, Feb. 26, 2015
Int. Cl. C12N 15/11 (2006.01); C12N 15/113 (2010.01); C07H 21/02 (2006.01)
CPC C12N 15/1135 (2013.01) [C07H 21/02 (2013.01); C12N 2310/14 (2013.01); C12N 2310/321 (2013.01); C12N 2310/344 (2013.01)] 26 Claims
 
1. An isolated double stranded nucleic acid (dsNA) comprising first and second nucleic acid strands and a duplex region of at least 25 base pairs, wherein each of said first and second nucleic acid strands comprises RNA and has a length which is at least 25 and at most 35 nucleotides, wherein said second oligonucleotide strand is perfectly complementary to SEQ ID NO: 4909 along at least 21 nucleotides of said second oligonucleotide strand length to reduce KRAS target gene expression when said double stranded nucleic acid is introduced into a mammalian cell.